September 2007

News

Eli Lilly Seeks European Approval of Alimta®

Eli Lilly is filing for European approval of its Alimta® Injection drug as an initial treatment for non-small cell lung cancer.

Eli Lilly & Co. Data Affirm Benefits of Using Alimta®

Eli Lily says that data from two large, open- label studies show patients experienced one-year survival rates above fifty percent when treated with Alimta®.

Free Mesothelioma Information Packet

Receive a comprehensive mesothelioma packet free of charge within 24 hours...

Yes   No

Join the Mesothelioma Community Network

Call Us Toll Free 1-800-336-0086

Top Doctors & Clinics, Treatment Protocols, Clinical Trials, FAQS

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

YesNo